Nautilus Biotechnology Inc’s recent filing unveils that its CFO and Treasurer Mowry Anna acquired Company’s shares for reported $11488.0 on May 29 ’25. In the deal valued at $0.77 per share,15,000 shares were bought. As a result of this transaction, Mowry Anna now holds 83,000 shares worth roughly $62250.0.
Then, Mallick Parag bought 12,000 shares, generating $8,788 in total proceeds. Upon buying the shares at $0.73, the Chief Scientist now owns 20,491,892 shares.
Before that, Mallick Parag bought 1,500 shares. Nautilus Biotechnology Inc shares valued at $1,098 were divested by the Chief Scientist at a price of $0.73 per share. As a result of the transaction, Mallick Parag now holds 20,493,392 shares, worth roughly $15.37 million.
Goldman downgraded its Nautilus Biotechnology Inc [NAUT] rating to a Sell from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including Guggenheim’s analysts, who began to cover the stock in late June with a ‘”a Buy”‘ rating. Morgan Stanley started covering the stock on January 06, 2022. It rated NAUT as “an Equal-weight”.
Price Performance Review of NAUT
On Tuesday, Nautilus Biotechnology Inc [NASDAQ:NAUT] saw its stock fall -2.72% to $0.75. Over the last five days, the stock has lost -2.19%. Nautilus Biotechnology Inc shares have fallen nearly -55.30% since the year began. Nevertheless, the stocks have fallen -71.98% over the past one year.
How much short interest is there in Nautilus Biotechnology Inc?
A steep rise in short interest was recorded in Nautilus Biotechnology Inc stocks on 2025-05-15, growing by 0.39 million shares to a total of 0.94 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-15 was 0.55 million shares. There was a rise of 41.75%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on November 02, 2021 when Cowen began covering the stock and recommended ‘”an Outperform”‘ rating.
